The standard first-line treatment for metastatic urothelial carcinoma has become the combination of Enfortumab Vedotin and Pembrolizumab following the publication of the EV-302 study results at the end of 2024. Another standard remains in 2025 for patients who are not eligible for the EV Pembrolizumab combination, namely platinum-based chemotherapy +/- avelumab in cases of non-progression. The objective of the FLORAL study is to determine the characteristics of these patients and the reasons that led clinicians to prefer a first-line treatment based on platinum salts.
Patients over 18 years of age
Metastatic urothelial carcinoma
Treated with first-line metastatic therapy since October 2024
Patient who expressed opposition to participating in the study
Adut atient with metastatic urothelial carcinoma and reated with first-line metastatic therapy since October 2024
Case-only
Retrospective
Not listed
Description of the clinical characteristics of patients recently treated with first-line metastatic therapy for urothelial carcinoma
Click on the lead sponsor to view all of their trials.
